This site is intended for healthcare professionals

bluebird bio announces temporary suspension on phase 1/II and Phase III studies of LentiGlobin gene therapy for sickle cell disease (bb1111).

Read time: 1 mins
Last updated:17th Feb 2021
Published:17th Feb 2021
Condition: Sickle Cell Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest